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Abstract
Background: Hepatitis C Virus (HCV) infection is a leading indication for liver transplantation. HCV infection reoccurs almost
universally post transplant, decreasing both graft longevity and patient survival. The immunosuppressant, cyclosporine A
(CsA) has potent anti-HCV activity towards both HCV replicons and the genotype 2a cell culture infectious virus. Previously,
we isolated mutations in the 1bN replicon with less sensitivity to CsA that mapped to both NS5A and NS5B regions of the
virus. Mutations in NS5A alone conferred decreased CsA susceptibility regardless of NS5B mutations.
Methodology/Principal Findings: We examined the mechanisms by which NS5A mutations contribute to CsA resistance
and if they are strain dependent. Using in vitro mutagenesis, the amino acid position 321 mutation of NS5A was restored to
the wild-type tyrosine residue conferring partial CsA susceptibility on the mutant replicon. The 321 mutation also alters CsA
susceptibility of the JFH cell culture virus. Additionally, we demonstrated a novel CsA-sensitive interaction between NS5A
and both cyclophilin A and B. Both the mutant NS5A and wild type NS5A bind cyclophilin in vitro. The NS5A: cyclophilin
interaction requires both the NS5A region identified by the resistance mutants and cyclophilin catalytic residues. In cell
culture, NS5A from CsA resistant mutant has an enhanced interaction with cyclophilin B. Additionally; NS5B facilitates a
stronger binding of mutant NS5A to endogenous cyclophilin B than wild-type in cell culture.
Conclusions/Significance: Collectively, this data suggests direct interactions between cyclophilins and NS5A are critical to
understand for optimal use of cyclophilin inhibitors in anti-HCV therapy.
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Introduction
HCV infects 200 million people worldwide. Current treatment
options for HCV include pegylated interferon a and ribavirin.
However this treatment is not always effective or tolerated well [1].
Thus, new therapies are urgently needed. Frequently, patients do
not have symptoms from HCV infection until their liver is severely
damaged. Liver transplantation becomes the only practical means
of restoring health and requires long-term immunosuppression to
prevent graft rejection. Almost every transplant patient receives
one of two different calcineurin inhibitors, either tacrolimus or
CsA. CsA and its nonimmunosuppressive analogs, DEBIO-25 and
NIM811, show in vitro antiviral activity against the HCV 1a, 1b,
and 2a experimental replicons that is related to their ability to
inhibit a class of cellular Prolyl-peptidyl isomerases called
cyclophilins (Cyp) [2,3,4]. Tacrolimus lacks this activity [4,5].
However, for transplant patients infected with HCV, it remains
unclear if CsA or tacrolimus is the calcineurin inhibitor of choice.
It was initially proposed that in vitro inhibition of HCV by CsA
results from disruption of the interaction between the HCV
polymerase, NS5B, and Cyclophilin B (CypB) [6]. CypB enhances
binding of NS5B to RNA [6,7,8]. A previous study showed CsA
addition to HeLa cell cultures results in relocalization and
secretion of CypB [9]. These findings were further corroborated
by recent clinical data from HCV and HIV co-infected patients.
The treatment of these co-infected patients with the CsA analog
Debio-025 results in a decrease of CypB levels in peripheral blood
mononuclear cells [10]. This decrease in CypB levels coincides
with a decrease in hepatitis C viral load. In contrast, Debio-025
treatment does not lead to decreases in Cyclophilin A (CypA)
levels [10]. While results are conflicting, siRNA data is most
consistent with CypA rather than CypB playing major role in
HCV subgenomic RNA replication [4,6,11,12,13]. Whether all
HCV replicons have the same cyclophilin requirement is unclear
[11]. Both CypA and CypB interact with the HCV NS5B
polymerase [13,14].
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resistant to CsA treatment [15]. Resistance mapped to two regions
of the HCV genome, NS5A and NS5B. All CsA resistant replicons
contain a set of similar, but not identical NS5A mutations, with
essentially the same NS5B mutations. Additionally, a mutant
replicon CsA-1s containing NS5A mutations alone confers as
much resistance as CsA-1s replicons containing mutations in both
NS5A and NS5B. Whether NS5A mutants are directly altering the
susceptibility of HCV replication to CsA, or indirectly modulating
the NS5B: cyclophilin interaction is unclear.
In this study we present data supporting a direct role of NS5A in
CsA resistance. The NS5A mutations from the 1bN replicon also
confer CsA resistance for the canonical Con 1b replicon. The
tyrosine residue at position 321 of NS5A is a particularly critical
determinant of CsA resistance. This residue is within the ‘277-334’
NS5B binding region of NS5A [16], but does not influence the
NS5A-NS5B interaction. We also demonstrate NS5A can bind
either CypB or CypA. A mutant NS5A is described that is more
resistant to the cellular effects of CsA inhibition despite a similar
biochemical binding to cyclophilins as wild-type NS5A. The
interaction between CypA and NS5A depends upon both catalytic
residues of CypA and domain 2/3 regions of NS5A where the cell
culture derived mutants map. In cell culture, the mutant shows
enhanced binding to CypB compared to wild-type NS5A.
Additionally, NS5B promotes stronger binding of the mutant
NS5A to CypB than wild- type NS5A. NS5A binding to
cyclophilins may thus be a sensitive determinant of the overall
susceptibility of HCV to cyclophilin inhibitors.
Materials and Methods
Ethics Statement
The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Cells and Plasmids
EN5.3 and Huh7.5 cells were used for all studies. Huh7.5 cells
and the Con1 HCV replicon were generous gifts from Dr. Charles
Rice. For these studies, the neomycin resistance gene was replaced
with a renilla luciferase-neo fusion gene amplified from a replicon
kindly provided by Drs. Ikeda and Kato [17]. The pNtat2ANeo/
SI plasmid containing the HCV 1bN consensus sequence
(GenBank accession no. AF139594) with an adaptive serine to
isoleucine change in the NS5A S232I was provided by Dr. Lemon
[18]. After transfection with replicon RNA, EN5.3 cells were
selected and maintained in growth media containing blasticidin
and 0.5–1.0 mg/ml G418 (Geneticin, Invitrogen, La Jolla, CA).
Huh7.5 cells were transfected and maintained in complete growth
media supplemented with non-essential amino acids and 0.5 mg/
ml G418.
Genetic manipulation and cloning of HCV Replicon
The CsA-3s NS5A (acc. No. EF115302) cloning was performed
as previously described [15]. The Chimeric Con 1b replicon was
generated as follows. Primers were designed to amplify two
separate PCR fragments from the Ntat/SI replicon genome to
eliminate the 4 amino acid SSYN insertion. New amplicons were
generated by overlap PCR using ultra Pfu polymerase (Stratagene,
La Jolla, CA). The fragments were cloned into a TOPO TA vector
(Invitrogen, Carlsbad, CA). The TOPO constructs were digested
with BlpI and ClaI and cloned into the original Con Luc Neo
plasmid vector. A similar cloning procedure was employed to
obtain Chimeric 3s. Quick-change mutagenesis was performed
using Topo Chimeric 3s amplicon as a template. To generate
different Chimeric 3s replicon variants, the BlpI –ClaI fragment
was inserted into the Con Luc neo plasmid to generate Chimeric
3s G256E, Chimeric 3s A280V, Chimeric 3s Q303L, Chimeric 3s
N321Y, Chimeric 3s G356R and Chimeric 3s A444V replicons.
RNA transcription and transfection
Replicon DNA was linearized with XbaI (NEB, Ipswich, MA)
and transcribed using a T7 Ampliscribe Flash transcription kit
(Epicenter Biotechnology, Madison, WI). RNA was transfected
into EN5.3 or Huh7.5 cells using the Transit mRNA transfection
kit (Mirus, Madison, WI). Three weeks after the establishment of
stable replicon cell lines using G418 selection, equal numbers of
replicon cells were seeded into 6 well plates with or without CsA.
The Secreted Alkaline Phosphatase (SEAP) assay was used to
quantitate the Ntat replicon RNA as described previously [19]. To
assay the Renilla luciferase activity, Con Luc Neo replicon cells
were lysed with 100 ml of Renilla Lysis buffer supplied with the
Renilla Luciferase Assay system (Promega, Madison, WI). 10 mlo f
clarified cell lysate was added to 50 ml of Renilla Luciferase Assay
buffer and read in triplicate on a Turner Designs TD20/20
Luminometer (Promega, USA).
Following the establishment of stable replicon cell lines, RNA
was isolated using the Trizol method. Total RNA was used for
cDNA synthesis using a primer located in N-terminal region of
NS5B. PCR was performed using this reverse primer and a
forward primer located within NS5A region. PCR product of the
expected size was excised from gel, purified and cloned into the
TOPO vector. Two clones from each mutant replicon were
sequenced with M13 forward and M13 reverse primers. The
results were analyzed and specific mutations were confirmed by
checking the chromatogram.
Transient Replication Assay
In vitro transcribed Con 1b RNA along with Chimeric 3s were
electroporated into ,4610
6 Huh7.5 cells. Following RNA
electroporation, one tenth of the cells were set aside to check the
luciferase activity at 4 hrs as an indicator of RNA electroporation
efficiency. The rest of the electroporated cells were equally divided
and plated into 24 wells so that each electroporation had 3 sets of 8
wells. Four wells of each set were left untreated while wells 5–8
were treated with 1.0 mg/ml of CsA until the assay was performed.
The cells were collected at 4 time points (24, 48, 72 and 96 hrs)
post RNA electroporation from both CsA treated and untreated
wells. Luciferase activity was monitored as above.
To monitor the replication assay in Huh7.5 cells, the cells were
pretreated with 1.0 mg/ml CsA for one week. These cells were
electroporated with either Con 1b or Chimeric 3s replicon RNA
and luciferase activity was monitored at 24, 48, 72 and 96 hrs. The
electroporations were performed in triplicate and average
luciferase activity for both Con1b and Chimeric 3s is presented.
Infectious virus recovery and Northern Blot assay
Infectious HCV particles were produced as described before
[20,21]. To observe the effect of CsA on infectious virion
production by JFH-wt and JFH-NS5A-Y325N (JFH-NS5A-
Y325N corresponds to the Y321N in Table 2A), 10 mg in vitro
synthesized RNA was electroporated in normal cells and in cells
pre-treated with 1.0 mg/ml CsA for one week. After 5 days, the
supernatants were collected, filtered through 0.45 mM filters and
passed onto naı ¨ve cells plated the day before. After 12 hrs,
supernatant were removed and either complete growth media or
media containing CsA was added. The plate was further incubated
for 72 hrs and Immunofluorescence assay was performed using
mAb to NS5A as described before [20].
HCV NS5A Cyclophilin Interact
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wt and a JFH1-Y325N mutant was electroporated into normal
Huh7.5 cells and cells already treated with 1.0 mg/ml of
cyclosporine for one week. The CsA-treated and electroporated
cells were further incubated in presence of CsA while normal cells
were grown in complete growth media. After 72 hrs post RNA
electroporation, cells were lysed in Trizol (Invitrogen, CA) and
total RNA was isolated following manufacturer’s protocol. The
northern blot was performed using standard molecular biology
protocols [22,23]. Approximately 20 mg of RNA was resolved by
glyoxal gel. The RNA was transferred onto nylon membrane and
cross-linked using UV. The probe was made with a Random
Priming DNA Labeling Kit (Roche, USA) using a DNA template
derived from NS5A C-terminal region and purified using Illustra
ProbeQuant G-50 Micro Columns (GE Health, USA). The
membrane was incubated with the above probe overnight and
washed once with low stringency and twice with high stringency
wash buffer provided with the NorthernMax kit (Applied
Biosystems). Hybridization of radiolabeled probe was visualized
using autoradiography and quantified using Storm followed by
image quant to obtain respective values. Data was normalized with
respect to actin gene hybridization for presentation.
Mammalian expression constructs
The wt NS5A-His (1bN-SI) and mt NS5A-His (CsA-3s)
constructs were made as follows. The NS5A genes were amplified
from the Ntat/SI and CsA-3s replicon by RT-PCR. Forward
primers were designed with an XhoI site and an in-frame start
codon ATG 59 to the NS5A sequence. The reverse primers
encoded a 6XHis tag in frame with the NS5A sequence, a stop
codon followed by Pac1 restriction site. The resulting PCR
product was cloned into XhoI-PacI digested pIRES/GFP (Green
Fluorescent Protein) mammalian expression vector (kindly pro-
vided by Dr. Kouacou Konan). The HA-wt NS5A and HA-mt
NS5A constructs were made by incorporating the HA tag
(MYPYDVPDYA) in the forward primer. The GFP gene in these
constructs was removed and the plasmid recircularized with T4
DNA ligase. For the N terminal truncated NS5A constructs
lacking domain 1 (D23NS5A), forward primers were designed to
encode a XhoI site, Kozak sequence, HA, the ATG start codon,
and NS5A sequence starting from amino acids 148 for both the
1bN and the CsA-3s replicon DNA templates. The reverse primers
contained an in-frame stop codon and a Pac1 site. The GFP gene
in these constructs was also removed and religated with T4 DNA
ligase. The Con1b NS5B was generated by using standard PCR
approach. The forward primer was designed to contain a FLAG
epitope (MDYKDDDDK) and cloned in a CMV-based mamma-
lian expression vector. The CypB mammalian expression vector
was generated with forward primers containing XhoI, ATG 59 to
the start of the CypB sequence and reverse primers containing an
HA tag, stop codon and a PacI site. The PCR fragment was then
cloned into the pIRES/GFP vector.
Immunoprecipitations
HA-wt NS5A and HA-mutant (mt) NS5A expression con-
structs were co-transfected with a FLAG-tagged Con 1b NS5B
expression construct in 293T cells using transit LT1 reagent
(Mirus, Madison, WI). Forty-eight hours after transfection, cells
were harvested and immunoprecipitated with HA-specific
antibody (Biodesign). Immunoprecipitates were separated using
SDS-10% Poly Acrylamide Gel Electropheresis (PAGE), and
western blotting was performed. Blots were probed with a
monoclonal NS5A-specific antibody (Biodesign) and a monoclo-
nal FLAG antibody against the FLAG tag of NS5B (Sigma). An
HRP-linked mouse secondary antibody specific for antibody light
chains (Jackson Immunological Research) was used and the
signal was developed using Immun-star HRP chemiluminescent
substrate (Bio-Rad, Hercules, CA). For NS5A and CypB
transfections, wt or mt NS5A-His and HA tagged CypB were
immunoprecipitated with His-specific monoclonal antibody
(Qiagen) bound to protein G agarose beads, washed, and loaded
onto a gel. The blots were probed with a NS5A monoclonal
(Biodesign) and a rabbit polyclonal to the HA tag. For the NS5A
and NS5B cotransfections, HA-wt NS5A and HA-mt NS5A were
cotransfected in 293T cells with FLAG Con1b NS5B. The lysates
were immunoprecipitated with HA-specific antibody and probed
with NS5A-, FLAG-, and CypB-specific antibodies to check
levels of NS5A, NS5B and CypB respectively.
Cyclophilin binding assay
Recombinant CypB was obtained as previously described [15].
GST-CypA was a generous gift from Dr. Carol Carter. Full-length
(HA-wt NS5A or HA-mt NS5A) or N-terminal truncated NS5A
constructs (D23NS5A), as well as N terminal FLAG-tagged Con
1b NS5B were in vitro translated in the presence of
35S
methionine/Cysteine (Expre
35S
35S protein labeling mix, NEN
Life Sciences, MA) using the TNT Quick coupled Transcription/
Translation Systems (Promega, Madison USA) following the
manufacturer’s protocol. The assay for GST-CypB binding to
NS5A or NS5B was performed as previously described [24]. In
brief, the radiolabelled proteins HA-wt NS5A and HA-mt NS5A
were incubated with approximately 2.0 mg of E.coli-expressed and
purified GST-CypB in binding buffer overnight. The bound
complex was washed 5 times with PBS containing 0.25% NP-40.
The complex was mixed with 26 SDS-PAGE sample buffer,
boiled for 5 minutes, and analyzed by SDS-10%PAGE along with
protein molecular weight markers (Precision Plus Protein Stan-
dard; Bio-Rad). The signal was developed after fluorography. In a
similar fashion the radiolabelled NS5A was incubated with
purified GST-CypA and binding was assessed. For CsA inhibition
in the binding experiment, drug was added to the binding buffer
followed by addition of NS5A and GST-CypA.
To further confirm the specificity of CypA NS5A binding, an
irrelevant protein, HIS tagged Cyan fluorescent protein (CFP) was
expressed in E. coli and purified using Ni
++ column following
manufacturers protocol (Qiagen). Approximately 2.0 mg of CFP
and NS5A proteins were incubated with equal amounts of purified
GST or GST-CypA proteins and binding was performed as
described before [24]. The complexes were resolved using SDS-
10% PAGE, and probed with anti-HIS monoclonal antibodies
(Qiagen) to detect HIS tagged proteins.
To map the region within NS5A responsible for binding, a
series of in-frame 90 amino acids deletion mutants were
generated in the HA-wt NS5A expressing plasmid. These
constructs were in vitro translated in presence of
35Sm e t h i o -
nine/cysteine and incubated with purified GST-CypA. The
binding was performed as above. The signal was developed after
fluorography and intensity of individual pull down signal was
quantified using image quant following Storm. To further map
the binding region within CypA, the two active site residues (R55
and F60) were mutated to Alanine. The
35S radiolabelled NS5A
was again incubated with eitherw tG S T - C y p Ao rm tG S T - C y p A
(carrying the two active site mutations) and binding was
performed as described above.
Statistical Analyses
The Student’s t test was used to calculate p values.
HCV NS5A Cyclophilin Interact
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Multiple NS5A mutant alleles alone can confer resistance
to CsA
In previously published work [15], we exposed the HCV
replicon to CsA for three weeks in culture and selected for
relatively resistant mutants. We sequenced replicon RNA from
surviving cells and found mutations in both NS5A and NS5B
regions. These NS5A and NS5B mutations were introduced into
the parental replicon [15]. The resulting replicons have lower
susceptibility to CsA compared to wild-type. The mutant replicon
CsA-1s 5A with mutations in NS5A alone has identical CsA
susceptibility to that seen for the CsA-1s replicon having both
NS5A and NS5B mutations [15]. It was unclear if the other NS5A
mutants are also able to replicate without mutations in NS5B. All
of the mutant replicons share a common set of 5 mutations in
NS5A, but differ at 1–2 additional amino acid residues. The CsA-
3s replicon is the most resistant of the CsA mutants. The mutant
NS5A from CsA-3s has an additional 325 mutation compared to
CsA-1s. It also lacks a mutation at 288 present in CsA-1s. The
NS5A gene of the CsA-3s replicon was cloned into the background
of the parental Ntat/SI replicon and stable replicon cell lines were
obtained with G418 selection. This replicon was referred to as
CsA-3s 5A. Stable cell lines were obtained for the Ntat/SI, CsA-3s
and CsA-3s 5A replicons. All 3 replicons were PCR amplified and
sequenced after G418 selection to look for any changes (reversions
or additions) that may have arisen during selection. No changes
were observed in NS5A in any of the replicons. We then compared
the CsA susceptibility of Ntat/SI, CsA-3s and CsA-3s 5A
replicons. The absolute SEAP values (a marker for HCV
replication) in absence of drug are similar between Ntat/SI and
CsA-3s and slightly lower for CsA-3s 5A (Fig. S1). Remarkably,
the CsA-3s 5A is equally resistant to CsA as the parent CsA-3s
containing both NS5A and NS5B mutations (Fig. 1). The CsA-3s
5A behaves similarly to the CsA-1s NS5A in conferring most of the
resistance to the mutant. Thus the role of NS5A in CsA
susceptibility is common among different mutants.
NS5A amino acid residue 321 plays a significant role in
resistance
The CsA-3s contains six point mutations in NS5A. It is unclear if
a single mutation accounts for resistance or if the mutations act
synergistically with each other. Despite the heterogeneity in NS5A
sequence none of these mutations are commonly present in the
extensive sequence banks of HCV isolated from patients (see
Table 1). We replaced individual NS5A mutations with the wild-
type original residue in context of the remaining five NS5A
mutations. We chose to revert individual mutations to the wild-type
amino acid because individual mutations may not have been viable
or functional for altered CsA resistance by themselves. These
mutant fragments were amplified without the SSYN 4 amino acid
insertion unique to the 1bN strain and cloned into the Con 1b
luciferase replicon which allows evaluation of the effect of each
mutant in a more typical HCV NS5A structure (Fig. 2A). A list of
replicons and mutations are shown in Fig. 2B. Without the SSYN,
the amino acid positions of the mutations now change by 4 amino
Figure 1. NS5A confers CsA resistance. Equal numbers of replicon cells were seeded for the Ntat/SI, CsA-3s and CsA-3s 5A cell lines. The cultures
were treated with CsA at the indicated concentrations for 6 days. Media was changed on day 6 and CsA was added to the cells again. On day 7, media
was collected and assayed for SEAP activity. They axis shows RSEAP Log10 (relative SEAP Log values). Student’s t test was used to calculate p values.
Ntat/SI vs CsA-3s 5A at 1.0 and 2.0 mg/ml ,0.0001; at 0.5 mg/ml is 0.0002.
doi:10.1371/journal.pone.0009815.g001
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was also constructed with the original 1bN NS5A, but lacking the 4
aminoacid insertion.Stablecell lineswereobtained forthechimeric
and wild-type Con 1b replicons. All of the replicons were PCR
amplified and sequenced again to confirm the sequence and check
for additional mutations. All the replicons retained mutations, and
no additional coding compensatory mutations were found except
for Chimeric 3s A444V which reverted back to Alanine. The
different replicons were treated with various concentrations of CsA
for 7 days. The cells were harvested and assayed for luciferase
activity. The absolute data is presented in Fig. S2 showing that the
luciferase activities in the absence of CsA are similar with the
exception of Chimeric 3s A444V which replicates better than the
others and after transfection reverted to A such that its coding
sequence is identical to Chimeric 3s, but lacks the SSYN insertion.
The Chimeric 3s replicon with all 6 CsA resistance mutations but
lacking the SSYN insert is still resistant to CsA (Fig. 2C). The
Chimeric 3s G260E, Chimeric 3s A280V, Chimeric 3s Q307L and
Chimeric 3s A444V mutants show as much resistance as the Con
1bN 3s (Fig. 2C). However, the Chimeric 3s N321Y mutant differs
in CsA sensitivity compared to Chimeric 3s. This mutant differs
from the Chimeric 3s in having the wild-type tyrosine instead of an
asparagine residue at amino acid 321. Its phenotype is intermediate
between the Con 1b (p#0.0001) and Chimeric-3s replicons
(p,0.0001). Thus, the tyrosine at residue 321 in NS5A appears to
play an important role in CsA sensitivity.
Transient replication assays were also performed to determine
the significance of NS5A mutations for CsA susceptibility.
Replicon RNA was electroporated into cells that were untreated
or treated with CsA and harvested at different time intervals to
examine the luciferase activity. The Chimeric 3s and Con1b
replicon replicate to similar levels (Fig. 2D). When CsA was added
to the Con1b and Chimeric 3s following RNA electroporation, the
Chimeric 3s replicates more effectively than wild- type (Fig. 2D).
This effect was even more pronounced when cells were pretreated
with CsA prior to RNA electroporation (Fig. 2E). As shown in
Fig. 2E, 72 hours after electroporation in the presence of CsA, the
Chimeric 3s replicon replicates to ,100 fold higher levels than the
wild-type. The Chimeric 3s N321Y with a single wild-type 321
residue (Y) and the remaining five 3s mutations replicated poorly
when compared with the other single revertants in similar
transient replication assays (data not shown).
To further evaluate the role of the 321 mutation by itself, we
engineered the 321 mutation in the background of the JFH1
infectious clone. The JFH1-Y325N and JFH1-wt produce a similar
number of infectious viral particles in the absence of CsA (Fig. 3A).
However, in the presence of CsA (gray bars), JFH1-wt produces
about 50% less infectious particles than JFH1-Y325N (Fig. 3A).
The viral replication was further examined by northern blot assay
and revealed similar levels of replication for both infectious clones
in normal Huh7.5 cells. But the JFH1-wt virus displays
approximately 20% less replication compared to JFH1-Y325N
in presence of CsA, demonstrating the crucial role of residue Y at
position 325 in CsA resistance (Fig. 3B).
Mutant NS5A does not differ from wild-type in binding
NS5B
NS5A binding to NS5B maps to two regions of NS5A, amino
acids 105–162 and 277–334 [16]. As the 321 residue of NS5A lies
in the second NS5B interaction site, it is possible that the mutant
NS5A differs from wild-type in NS5B binding. To investigate the
NS5A-NS5B interaction, 293T cells were transfected with either
HA-wt NS5A (1bN, wild-type) or HA-mt NS5A (CsA-3s, mutant),
along with FLAG-tagged NS5B. Cell lysates were immunoprecip-
itated with HA-specific antibody and probed with anti-FLAG
mAb to detect NS5B. We detected no difference in binding NS5B
between wt NS5A and mt NS5A (Fig. 4, lanes 2 and 3). The pull
down of NS5B is specific since no NS5B is brought down with the
empty vector control (Fig. 4, lane 1).
Both CypB and CypA directly bind NS5A, and this binding
requires cyclophilin catalytic residues
It has previously been shown that NS5B binds both CypB and
CypA [13,14]. However, prior genetic evidence suggested that
Table 1. Conservation of amino acids at positions identified by 3s mutant in HCV sequenced from genotype 1 patients.
Amino Acids Genotypes Comments
1b 1a 1 1g 1c
Gly 260 178/1203 43/208 115/115 1/1 1/2 High frequency of D,A,Q at position 260 for 1b,
High frequency of A,T,Q,M at position 260 for 1a
Val 284 140/1203 38/208 45/115 0/1 1/2 All non V positions were Ile
Leu 307 1200/1203 208/208 115/115 1/1 2/2 2 L to P changes AM401923, DQ492170,
1 L to Q change DQ491971
Asp 320 1196/1203 208/208 115/115 0/1 1/2 3 D to E changes AF033364,AY808017, EF4075003
D to G changes AM493473, DQ492132, DQ492178 1
D to N change AY808033
1G = AM910652
Tyr 325 1197/1203 208/208 115/115 1/1 2/2 2 Y to C changes AM401892, AM401974
2 Y to D changes DQ491959, DQ491965
1 Y to H change AF033361
1 Y to N change DQ492001
Val 356 1198/1203 208/208 115/115 1/1 2/2 2 R to Q change
1 R to W change
2 R to L change
Gly 448 1097/1203 208/208 115/115 1/1 2/2 4 V to I changes AF033364, AY808017,
EF407500 1 V to A change AU402225
1 V to G change AM402246
doi:10.1371/journal.pone.0009815.t001
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Previous studies did not address the role of NS5A in cyclophilin
binding. To determine if CypB interacts with NS5A, HA-wt NS5A
and HA-mt NS5A were in vitro translated with
35S methionine/
cysteine and proteins were incubated with GST-CypB or GST
alone. The in vitro translated NS5B was used as a positive control
Figure 2. CsA sensitivity of different chimeric 3s replicons. (A) Schematic representation of different Chimeric replicons derived from Con1b and
Ntat/SI. Star represents all 3s mutants (acc. no. EF115302), SSYN insert present only in 1bN replicon. = Con1b sequence, = 1bN sequence. (B) List of
cyclosporineresistantmutationsclonedinacon1bbackground.Starindicatesreversionofthatparticularaminoacid.(C)Equalnumbersofrepliconcells
were seeded for the Con 1b, Chimeric Con1b, and Chimeric 3s variants. The cells were treated with different concentrations of CsA as indicated on the x
axis and assayed for luciferase activity. The y axis shows relative light units Log values (RLULog10). Error bars represent standard deviations from three
separate experiments read in triplicate. Student’s t test was used to calculate p values. Con 1b vs Chimeric 3s N321Y P,0.0001 at 1, 1.5, and 2.0 mg/ml
CsA. Chimeric3sN321Yvs Chimeric3sP,0.0001 at1,1.5,and2.0 mg/ml CsA. (D) Huh7.5cells were electroporated withChimeric Con1bandChimeric3s
replicon RNA and plated in either the presence or absence of 1.0 mg/ml CsA. Equal numbers of cells were harvested at 24, 48, 72, and 96 hours and
analyzed for luciferase activity (RLULog10). Three independent RNA electroporations were performed and average luciferase readings are presented for
the indicated time points. Error bars represent standard deviation (E) Huh7.5 cells were electroporated as in (D) except the cells were pretreated with
1.0 mg/ml CsA for 6 days and plated in the presence of drug. Equal numbers of cells were collected and luciferase activity was analyzed (RLULog10). The
average of three independent RNA electroporations is presented. Error bars represent standard deviation.
doi:10.1371/journal.pone.0009815.g002
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CypB (Fig. 5A). GST alone did not show an interaction with either
version of NS5A. We also tested if NS5A bound CypA, and found
a more pronounced difference between the binding of HCV
proteins to CypA compared with CypB (Fig. 5B). This data
suggests that for CypB, NS5A binds CypB almost as well as NS5B
does, whereas for CypA, the CypA:NS5A interaction is weaker
than the CypB:NS5B interaction. We also tested whether or not
recombinant NS5A purified from E. coli binds GST only when
fused to CypA and if unrelated proteins such as CFP bind
GSTCypA. The CFP along with other Ni
++ purified proteins are
shown in supplemental data NS5A (Fig. S5B) confirming that the
GSTCypA fusion protein does not bind all proteins with prolines
present and that the GSTCypA:NS5A interaction is specific.
All of the CsA resistant mutations fall in domain 2 and 3 of
NS5A. To determine which region of NS5A was critical in binding
CypB, N terminal deletions of wild-type and mutant CsA-3s NS5A
were constructed which lacked domain 1 and binding was
performed as above. Both wt D23 NS5A and mt D23 NS5A
bind CypB with same efficiency (supplemental data, Fig. S3).
Thus, domains 2 and 3 of NS5A are sufficient to bind both CypB
and CypA. We mapped the NS5A interacting region with CypA
by generating NS5A mutants containing 90 amino acid in-frame
deletions and performed a CypA binding assay. We observed
much of the binding maps to the C-terminal region of NS5A, in
particular amino acids ranging from 361–451 where a majority of
the binding interaction is lost and only 5% of input is retained
(Fig. 5C). The NS5A deletion ranging from amino acids 271–360
binds approximately 8–9% of the input NS5A, while deletion of
the first 180 amino acids does not have a major defect in binding
to NS5A. This data indicates the CypA binding regions are
clustered in second half of NS5A in between amino acids 181–451.
The Prolyl-peptidyl Isomerase (PPI) activity of CypA catalyzes
the cis-trans isomerization of peptide bonds that connect prolines.
To examine the role of the catalytic domain of CypA in HCV
NS5A binding we converted the two amino acids (R55 and F60) in
the catalytic domain to alanine. The mutant protein was then
tested for its ability to pull down NS5A. Using the GST pull down
assay, the CypA mutant protein displays complete loss of binding
to NS5A indicating crucial involvement of the active site residues
in NS5A binding (Fig. 5D).
Mutant NS5A facilitates the interaction of NS5B and CypB
in cell culture
To determine if the interaction between NS5A and CypB
occurs in vivo, 293T cells were co-transfected with His-tagged wt-
NS5A or mt- NS5A along with CypB-HA. The cells were lysed
and immunoprecipitated with anti-His antibody to purify NS5A-
Figure 3. Replication of JFH1 infectious clone carrying a Y325N mutation in the presence and absence of CsA. (A) Infectivity of in vitro-
transcribed RNA from JFH1-Y325N and JFH1-wt were determined by infectious center assay. Huh7.5 cells were electroporated with RNA transcripts
and cleared supernatant was examined for number of infectious particles by serially diluting and passing on to fresh Huh7.5 cells. The infectious
centers were monitored by immunofluorescence assay by using anti-NS5A monoclonal antibodies. Y axis shows number of infectious virus produced.
The average of two independent experiments with error bar representing standard deviation is presented. Student’s t test was used to calculate p
values. JFH1-wt vs JFH1-wt-CsA, p=0.012, indicated by star. (B) Northern blot analysis of total RNA from either non treated or pretreated Huh7.5 cells
electroporated with RNA from JFH1-Y325N and JFH1-wt. Total RNA was isolated from these cells and analyzed by probing with
32P-labeled random
probe derived from C-terminal portion of NS5A. The signal was quantified with Storm and the reading was normalized with respect to actin control.
The y axis represents relative transcript levels with JFH1-Y325N arbitrarily set to 100%.
doi:10.1371/journal.pone.0009815.g003
Figure 4. Wild-type and mutant NS5A’s do not differ in binding
NS5B. 293T cells were co-transfected with either HA-wt NS5A or HA-mt
NS5A together with FLAG-wt NS5B (Con 1b). The cells were harvested
48 hours after transfection and immunoprecipitated with HA-specific
antibody. Immunoprecipitates were western blotted and probed with
monoclonal antibody specific for NS5A and anti-FLAG antibody to
detect NS5A and NS5B respectively. Signal was detected by chemilu-
minescence assay (IP-immunoprecipitation, IB-immunoblot).
doi:10.1371/journal.pone.0009815.g004
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PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9815Figure 5. NS5A binds both CypB and CypA. (A) wt-NS5A, mt-NS5A, and wt NS5B-FLAG (1bN) were labeled with
35S methionine/cysteine by in
vitro translation. Labeled proteins were incubated with either GST alone (Lanes 2, 5, and 8) or GST-CypB (Lanes 3, 6, and 9). Gluthathione Sepharose
beads were used to purify GST-containing complexes from the binding mixture. After separation via SDS-PAGE,
35S-labeled proteins were detected by
autoradiography. Lanes 1, 4, and 7 contain labeled proteins used in the binding assay. (B) The wt-NS5A, mt-NS5A, and wt NS5B-FLAG (Con 1b) were in
vitro translated and incubated with either GST alone or GST-CypA. The GST binding assay was performed as described in (A). The left three lanes
contain labeled proteins used in the binding assay. (C) The binding region within the NS5A region for CypA was mapped by generating 90 amino
acids in-frame deletion mutants. The radiolabeled mutant proteins were incubated with GST-CypA as above. Input protein (I) was loaded at 1/5
volume alongside the corresponding pull-down product (P). Pulled down signal was quantified using Storm and % values of pull down are shown for
each deletion mutant. (D) The CypA containing mutations in the isomerase active site was analyzed for binding to wt-NS5A using GST binding assay.
doi:10.1371/journal.pone.0009815.g005
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NS5A-specific antibodies and HA-specific antibody to detect
CypB. Both wt NS5A and mt NS5A interact with CypB-HA
(Fig. 6A, lanes 2 and 4). However, mt NS5A binds substantially
greater amounts of CypB than wt NS5A. CypB-HA is not
immunoprecipitated in the absence of NS5A (Fig. 6A, lane 1,
empty vector control). Co-transfections of wild-type and mutant
NS5A with CypB are both disrupted by treatment of transfected
cells with 2 mg/ml of CsA (Fig. 6A, lanes 3 and 5). Several
attempts were made to pull down endogenous CypB from cells
using transfected and replicon cells, however no CypB can be
pulled down by NS5A alone (data not shown). However,
transfected NS5A is successful at pulling down endogenous CypB
(similar to replicon setting) only in the presence of NS5B (Fig. 6B,
lanes 4 and 5). It is possible that when CypB is present in large
amounts, it can out compete other cellular factors that target
NS5A. However in the presence of replicon levels of HCV
proteins and endogenous CypB, the lower levels of CypB do not
stably out compete the other cellular NS5A binders unless NS5B is
present to facilitate NS5A interaction with CypB. Nevertheless, the
mutant’s interaction with NS5B is enhanced beyond that of wild-
type NS5A. Similar coimmunoprecipitations were performed in
Huh 7.5 cells and showed the same results (Fig. S4).
Discussion
Cyclophilins have now been implicated in the life cycle of
several different DNA and RNA viruses [25,26,27,28]. In one
particularly well-studied example, CypA binds the HIV Gag
protein and is incorporated into the virion in addition to binding
incoming HIV capsid protein. However, the mechanistic role of
CypA in HIV remains unclear despite intense investigation and
detailed structural insights [29,30]. It was initially proposed that
CsA inhibits HCV by blocking the interaction between the active
site of CypB and the viral polymerase NS5B [6]. Although NS5B
has largely been thought of as the principal mediator of CsA
action, genetic mapping of CsA resistance implicated NS5A as
being the principal gene [15] and recently it was shown that the
presence of NS2 also modulates CsA susceptibility [31] although
in the case of NS2 it remains unclear if NS2 directly bind
cyclophilins. The main finding in the current study is that NS5A
directly binds cyclophilins, and that its interaction is weaker in
vitro than that of NS5B and cyclophilins. Since cyclophilin: HCV
interactions also occur in vivo [10], our data suggests NS5A
variants may have the largest effect on susceptibility and clinical
resistance to cyclophilin inhibitors will arise first in NS5A mutants
before NS5B mutants. We previously selected HCV replicons that
could grow in the presence of CsA [15]. Mutations mapped to
both NS5A and NS5B regions. Several groups have also found
that NS5A mutations alter the sensitivity of the replicon to
cyclophilin inhibitors in cell culture [32,33]. We show a cell free
direct interaction with both CypA and CypB, recent evidence
support that CypA not CypB is the most relevant cyclophilin in
most Huh7 cell lines [13], although nonCypA cyclophilins may
play a role in some cell lines [33].
The barrier to resistance for CsA is relatively high compared to
other antivirals in which a single mutation confers substantial
resistance. The different mutant NS5A sequences localize to
Figure 6. Mutant NS5A binds CypB better than wild-type NS5A in cells. (A) 293T cells were co-transfected with either wt-NS5A-His (lanes 2
and 3) or mt- NS5A-His (lanes 4 and 5) together with HA-tagged CypB in the presence and absence of 2.0 mg/ml CsA. Forty eight hours after
transfections, cell lysates were immunoprecipitated with anti-His antibody. The immunoprecipitates (IP) were Western blotted and probed with
NS5A-specific and HA-specific antibodies to detect NS5A and CypB respectively. Lane 1 represents transfections with an empty vector control. (B)
293T cells were co-transfected with either HA-wt NS5A (lanes 3 and 5) or HA-mt NS5A (lanes 2 and 4) in the presence (lanes 4 and 5) or absence (lanes
1–3) of FLAG-wt NS5B (Con 1b). Lane 1 represents transfections with an empty vector control. Forty eight hours after transfections, cell lysates were
immunoprecipitated with anti-HA antibody and Western blotted. The blots were probed with antibodies specific for NS5A (top blot), FLAG (to detect
NS5B (middle blot), and CypB (lower blot) respectively. Upper two blots show total cell lysate without HA-specific immunoprecipitation.
doi:10.1371/journal.pone.0009815.g006
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from one strain (1bN) also affects other genotype 1b strains
(Con1b) and even a genotype 2a (JFH) (Fig. 3). The affect on JFH
is despite the previously reported observation that JFH replication
is not as dramatically dependant on cyclophilins [11]. HCV is
classified into 6 divergent genotypes and has extensive sequence
variation even within each genotype. None of these CsA resistance
mutants occur frequently in any of the 6 genotypes. Due to the
large amount of error prone replication that occurs in patients
over decades, even variants with some fitness cost may
occasionally become fixed in an individual. We examined
.1200 genotype 1 sequences and found that our in vitro selected
mutations did not occur frequently. Remarkably little variation
occurred at 321, and the Y to N variant at 321 is present in less
than 0.1% of genotype 1 (Table 1). While some of these sequences
were likely from HCV infected transplant patients, the clinical
data associated with these sequences is insufficient to determine
with certainty if any specific patient was exposed to CsA.
A Chimeric 3s N321Y replicon was constructed restoring the
asparagine mutation at amino acid position 321 to the wild-type
tyrosine residue. This mutant replicon, contains all of the other
CsA-3s mutations, but lacks the mutation at 321. Chimeric 3s
N321Y is more sensitive to CsA treatment than Chimeric 3s
suggesting a tyrosine residue at position 321 contributes to some
but not all of the CsA sensitivity. This mutation is in a region of
NS5A that binds NS5B [16] and targets a residue previously
shown to be critical for RNA replication [34]. However, our
studies showed that mutant does not differ from wild-type in its
interaction with NS5B (Fig. 4). Even the most structured part of
NS5A, domain I, apparently has multiple conformations [35,36].
Therefore, it is hard to know the conformational effect of the
tyrosine at residue 321 NS5A in domain 2 at this time. Certainly a
conformational effect could explain the observed difference
between the Con1b and Chimeric-3s replicons in cyclophilin
binding. The interaction of truncated NS5A molecules with
cyclophilins localizes the CypA: NS5A and CypB: NS5A binding
region(s) to domains 2 and 3 of NS5A. The NS5A residues 360–
440 provide slightly more of the binding affinity than 270–360.
The importance of the 321 residue that we show here is consistent
with a recent NMR structural study provided evidence that for at
least JFH2a NS5A, domain 2, including residue 321 specifically
makes an important interaction with cyclophilins (particularly
CypA which binds a larger motif than CypB). Still peptides
containing 321 accounted for only one tenth of the binding
strength of all domain 2 [37]. It is possible that 321 variation
results in a conformational change in NS5A that may affect other
residues either adjacent or more distant. Our data suggests that at
least for genotype 1 NS5A, a domain 3 cyclophilin interaction may
also be important.
The interaction between NS5B and cyclophilins has been
demonstrated by several groups. In one study, CsA was used to
select mutations in NS5B using a HCV replicon with GFP inserted
into NS5A [38]. The GFP-containing NS5A may be distinct in
conformation from wild-type. It is possible that NS5B: Cyp
interaction is the most CsA susceptible genetic locus when GFP is
inserted in domain 3 of NS5A, while the NS5A: Cyp interaction is
the more important locus in a non-tagged NS5A.
Previous functional studies have investigated the interaction of
NS5B alone and cyclophilins. Here, we show a novel interaction
between NS5A and both CypA and CypB. Mutant NS5A binds
CypB to a greater extent than wild-type in cells (Fig. 6 and S4). In
this study with tagged CypB the wild-type interaction was barely
detected while the mutant interaction was strong (Fig. 6A). The
GST pull-down assay for CypA binding does not reflect a
difference between wild-type and mutant NS5A in either CypA or
CypB (Fig. 5). We speculate that this discrepancy is due to the
absence of other NS5A cellular binding partners in the GST assay.
We made several attempts to immunoprecipitated endogenous
CypA and CypB with NS5A (data not shown). Neither
endogenous CypA nor CypB could be pulled down by NS5A
expressed alone in cells. It is possible the NS5A: cyclophilin
interaction cannot stably compete with other NS5A partners in the
absence of other viral proteins such as NS5B. NS5A could pull
down endogenous CypB only in the presence of NS5B (Fig. 6B).
NS5A did not immunoprecipitate CypA even in the presence of
NS5B (data not shown). Endogenous CypB levels in Fig. 6B may
primarily reflect NS5B pull down of CypB. However, such a
possibility is unlikely as the amount of CypB immunoprecipitated
would have been relatively equal between wild-type and mutant
NS5A. In either case, mutant NS5A either by itself or through its
interaction with NS5B has an enhanced CypB interaction.
It is unclear if cyclophilins assist in folding NS5A and NS5B or,
alternatively, form part of the HCV replication complex. It is
possible that cyclophilins allow both NS5A and NS5B to access
important conformations. Alternately, binding of both NS5A and
NS5B to cyclophilins may facilitate incorporation of cyclophilins
into the replication complex. Either way the catalytic portion of
cyclophilins is critically involved in NS5A (Fig. 5D) just as it is in
NS5B [8]. We cannot genetically dissect if cyclophilins only need
to bind HCV proteins, or if they bind and catalyze isomerization
around the proline bond. CsA disrupts NS5A’s interaction with
both CypA and CypB (Fig. 6A) as well as NS5B and CypB (data
not shown). While the downstream effects of this disruption are
unclear, an enhanced interaction of 3s mutant NS5A to both
CypA and CypB could allow the mutant to retain either
cyclophilin at low concentrations of CsA. Further study into the
details of NS5A interactions with cyclophilins should shed light on
how best to pair non immunosuppressive cyclophilin inhibitors
with other small molecules to inhibit viral proteins in the replicase
complex.
Supporting Information
Figure S1 The absolute value of data presented in Fig. 1.
(ASEAP Log10 indicates the absolute SEAP Log values)
Found at: doi:10.1371/journal.pone.0009815.s001 (0.15 MB TIF)
Figure S2 The absolute value of data presented in Fig. 2B.
(ALUL Log10 indicates absolute light unit Log values)
Found at: doi:10.1371/journal.pone.0009815.s002 (0.25 MB
TIF)
Figure S3 NS5A constructs without domain1 (wt D23 NS5A, mt
D23 NS5A) were translated in vitro and incubated with either
GST alone or GST-CypB as described in Fig. 5A. 35S labeled
GFP protein was used as a negative control for binding.
Found at: doi:10.1371/journal.pone.0009815.s003 (0.80 MB TIF)
Figure S4 Mutant NS5A binds CypB better than wild-type
NS5A. Huh7.5 cells were co-transfected with either HA-wt NS5A
or HA-mt and wt NS5B (Con 1b) in the presence of CypB-FLAG
tagged plasmid. Forty eight hours after transfections, cell lysates
were immunoprecipitated with anti-HA antibody and Western
blotted with anti-FLAG (bottom panel). The top panel shows
probing the total cell extract with anti-FLAG antibodies to
demonstrate equivalent CypB expression.
Found at: doi:10.1371/journal.pone.0009815.s004 (0.38 MB TIF)
Figure S5 HCV NS5A binds CypA A) Coomassie staining of
HIS-tagged E. coli purified proteins B) Western blot analysis using
anti-HIS monoclonal antibody demonstrates NS5A in the
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GST or GSTCypA.
Found at: doi:10.1371/journal.pone.0009815.s005 (3.00 MB TIF)
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